Bobitt Julie, Kang Hyojung, Arora Kanika, Bhagianadh Divya, Milavetz Gary, Kaskie Brian
University of Illinois Chicago, Department of Medicine, Center for Dissemination and Implementation Science.
University of Illinois Urbana Champaign, College of Applied Health Sciences, Department of Kinesiology and Community Health.
Cannabis. 2023 Jul 5;6(2):113-122. doi: 10.26828/cannabis/2023/000125. eCollection 2023.
Chronic pain (CP) is experienced by as many as 50 million Americans and can negatively impact physical and mental health. Prescribing opioids is the most common approach to address moderate to severe CP though these potent analgesics are associated with a significant number of side effects. One alternative some Americans are turning to for CP management is cannabis. In addition to serving as an alternative, many individuals with CP use cannabis in addition to using prescription opioids. This study examined individuals with CP who enrolled in the state of Illinois' opioid diversion program, the Opioid Alternative Pilot Program (OAPP), which offers individuals aged 21 and older a separate pathway to access medical cannabis if they have or could receive a prescription for opioids as certified by a licensed physician.
Cross-sectional survey data were collected from 450 participants. We described participants and compared those who use only cannabis with those who use cannabis and opioids.
While 16% of the respondents were cannabis-only users, 84% of the respondents were co-users of opioids and cannabis. Both groups considered opioid use risky (100% cannabis-only, 89% co-users,). The majority (73%) of respondents sought to completely stop or never start using opioids for CP. Cannabis-only users reported lower levels of pain compared to co-users. Co-users (85%) were more likely to have their routine provider as a cannabis certifying physician than cannabis-only users (69%).
With increasing clinical evidence, legalization and acceptance, researchers should continue to examine how cannabis may be a viable alternative to reduce the risk of prescription opioid side effects, misuse, or dependence. Our findings also inform health care providers and state policymakers who increasingly are being asked to consider how cannabis may reduce the potential for harmful outcomes among persons with CP who use prescription opioids.
多达5000万美国人遭受慢性疼痛(CP),这会对身心健康产生负面影响。开具阿片类药物是治疗中度至重度CP最常见的方法,不过这些强效镇痛药会带来大量副作用。一些美国人转向使用大麻来管理CP。除了作为一种替代方法外,许多CP患者在使用处方阿片类药物的同时还使用大麻。本研究调查了参加伊利诺伊州阿片类药物转移计划——阿片类药物替代试点计划(OAPP)的CP患者,该计划为21岁及以上的个人提供了一条单独的途径,即如果他们拥有或可以获得持牌医生开具的阿片类药物处方,就可以获取医用大麻。
收集了450名参与者的横断面调查数据。我们描述了参与者,并比较了仅使用大麻的人和同时使用大麻和阿片类药物的人。
虽然16%的受访者仅使用大麻,但84%的受访者同时使用阿片类药物和大麻。两组都认为使用阿片类药物有风险(仅使用大麻者为100%,同时使用者为89%)。大多数(73%)受访者试图完全停止或从未开始使用阿片类药物治疗CP。与同时使用者相比,仅使用大麻者报告的疼痛程度较低。同时使用者(85%)比仅使用大麻者(69%)更有可能让其常规医疗服务提供者作为大麻认证医生。
随着临床证据的增加、大麻合法化及被接受程度提高,研究人员应继续研究大麻如何成为降低处方阿片类药物副作用、滥用或依赖风险的可行替代方法。我们的研究结果也为医疗保健提供者和州政策制定者提供了参考,他们越来越多地被要求考虑大麻如何降低使用处方阿片类药物的CP患者出现有害后果的可能性。